Journal article
Statin use is safe and does not impact prognosis in patient with de novo follicular lymphoma treated with immunochemotherapy: An exploratory analysis of the PRIMA cohort study
E Bachy, JA Estell, E Van de Neste, R Bouabdallah, J Bargay, A Delmer, B Gelas-Dore, M Gomes da Silva, O Fitoussi, D Belada, H Maisonneuve, T Intragumtornchai, T Lamy, P Dartigues, J Francis Seymour, G Salles
American Journal of Hematology | WILEY | Published : 2016
DOI: 10.1002/ajh.24305
Abstract
An adverse prognostic impact of statin use in lymphoma was first suspected from in vitro data showing an impairment of anti-CD20 antibody binding. However, further clinical studies suggested an improved outcome associated with their use in hematological malignancies. In particular, a survival benefit was reported for patients with follicular lymphoma on statins. Our objective was to assess the outcome of follicular lymphoma patients treated in the PRIMA study with immunochemotherapy according to the use of statins. Among the 1,217 patients enrolled in the PRIMA study, 1,135 were included in the present study. Concomitant treatments at registration were available for all patients. Among those..
View full abstract